# Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

> **NCT04320277** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Hospital of Prato** · enrollment: 200 (estimated)

## Conditions studied

- Pharmacological Action

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT04320277
- **Lead sponsor:** Hospital of Prato
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-16
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-07-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04320277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04320277, "Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04320277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*